SNORD113-3 enhances the expression of ADAR2, which promotes the editing of PHKA2 and subsequently regulates glucose and lipid metabolism as well as glioblastoma progression via the PHKA2/EBF1 axis [387]. Here, PHKA2 is linked to glioblastoma.